

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT										
NATURE OF CONVEYANCE:	ASSIGNMENT										
CONVEYING PARTY DATA											
<table border="1"> <thead> <tr> <th>Name</th> <th>Execution Date</th> </tr> </thead> <tbody> <tr> <td>Ugur Sahin</td> <td>11/06/2012</td> </tr> <tr> <td>Ozlem Tureci</td> <td>11/07/2012</td> </tr> <tr> <td>Michael Koslowski</td> <td>11/23/2012</td> </tr> <tr> <td>Rita Mitnacht-Kraus</td> <td>11/08/2012</td> </tr> </tbody> </table>		Name	Execution Date	Ugur Sahin	11/06/2012	Ozlem Tureci	11/07/2012	Michael Koslowski	11/23/2012	Rita Mitnacht-Kraus	11/08/2012
Name	Execution Date										
Ugur Sahin	11/06/2012										
Ozlem Tureci	11/07/2012										
Michael Koslowski	11/23/2012										
Rita Mitnacht-Kraus	11/08/2012										
RECEIVING PARTY DATA											
<table border="1"> <tr> <td>Name:</td> <td>Ganymed Pharmaceuticals AG</td> </tr> <tr> <td>Street Address:</td> <td>Freiligrathstrasse 12</td> </tr> <tr> <td>City:</td> <td>Mainz</td> </tr> <tr> <td>State/Country:</td> <td>GERMANY</td> </tr> <tr> <td>Postal Code:</td> <td>55131</td> </tr> </table>		Name:	Ganymed Pharmaceuticals AG	Street Address:	Freiligrathstrasse 12	City:	Mainz	State/Country:	GERMANY	Postal Code:	55131
Name:	Ganymed Pharmaceuticals AG										
Street Address:	Freiligrathstrasse 12										
City:	Mainz										
State/Country:	GERMANY										
Postal Code:	55131										
<table border="1"> <tr> <td>Name:</td> <td>Johannes Gutenberg-Universitat Mainz</td> </tr> <tr> <td>Street Address:</td> <td>Saarstrasse 21</td> </tr> <tr> <td>City:</td> <td>Mainz</td> </tr> <tr> <td>State/Country:</td> <td>GERMANY</td> </tr> <tr> <td>Postal Code:</td> <td>55122</td> </tr> </table>		Name:	Johannes Gutenberg-Universitat Mainz	Street Address:	Saarstrasse 21	City:	Mainz	State/Country:	GERMANY	Postal Code:	55122
Name:	Johannes Gutenberg-Universitat Mainz										
Street Address:	Saarstrasse 21										
City:	Mainz										
State/Country:	GERMANY										
Postal Code:	55122										
PROPERTY NUMBERS Total: 1											
<table border="1"> <thead> <tr> <th>Property Type</th> <th>Number</th> </tr> </thead> <tbody> <tr> <td>Application Number:</td> <td>13636277</td> </tr> </tbody> </table>		Property Type	Number	Application Number:	13636277						
Property Type	Number										
Application Number:	13636277										
CORRESPONDENCE DATA											
Fax Number:	3127758100										
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>											
Phone:	3127758000										
Email:	rkieltyka@mcandrews-ip.com										
Correspondent Name:	McAndrews, Held & Malloy Ltd.										
Address Line 1:	500 W. Madison St.										

CH \$40.00 13636277

Address Line 2: Ste. 3400
Address Line 4: Chicago, ILLINOIS 60661

ATTORNEY DOCKET NUMBER: 25923US01

NAME OF SUBMITTER: Timothy M. Long

Total Attachments: 9
source=25923US01_Assignment_SN13636277#page1.tif
source=25923US01_Assignment_SN13636277#page2.tif
source=25923US01_Assignment_SN13636277#page3.tif
source=25923US01_Assignment_SN13636277#page4.tif
source=25923US01_Assignment_SN13636277#page5.tif
source=25923US01_Assignment_SN13636277#page6.tif
source=25923US01_Assignment_SN13636277#page7.tif
source=25923US01_Assignment_SN13636277#page8.tif
source=25923US01_Assignment_SN13636277#page9.tif

PATENT ASSIGNMENT

WHEREAS, we, Ugur Sahin, Özlem Türeci, Michael Koslowski, and Rita Mithnacht-Kraus (collectively the "the Assignors") have made new and useful inventions and improvements disclosed in a United States patent application entitled "MONOCLONAL ANTIBODIES FOR TREATMENT OF CANCER" and identified as Case No. 25923US01 in the offices of McANDREWS, HELD & MALLOY, LTD., filed on September 20, 2012, in the United States Patent and Trademark Office as Serial No. 13/636,277 (the "277 Application").

WHEREAS, Ganymed Pharmaceuticals AG, a German corporation having a place of business at Freiligrathstrasse 12, Mainz, Germany 55131, together with Johannes Gutenberg-Universität Mainz, having a place of business at Saarstrasse 21, Mainz, Germany 55122, (collectively "the Assignees") is desirous of acquiring the title, rights, benefits, and privileges hereinafter recited.

NOW, THEREFORE, in exchange for good and valuable consideration in hand paid the receipt, adequacy, and sufficiency of which are hereby acknowledged, the Assignors hereby assign to the Assignees, their successors and assigns, the entire right, title and interest in and to said application and the inventions and improvements disclosed therein, and in any and all other United States (provisional or non-provisional) applications based thereon or that claim priority thereto, including any continuation, continuation-in-part, divisional application that the Assignors may file, either solely or jointly with others, and in any and all Letters Patent of the United States that may be obtained on any of said applications, and in any reexamination, renewal, substitution, reissue or extension of such applications or patents, and every priority right that is or may be predicated upon or arise from said inventions, improvements, applications, and Letters Patent.

The Assignors hereby authorize the Assignees to file patent applications in any or all countries for any or all of said inventions and improvements in our name or in the names of the Assignees or otherwise as said Assignees may deem advisable, under the International Convention or otherwise. The Assignors further acknowledge the assignment of all domestic and foreign intellectual property rights to the Assignee(s) related to the '277 Application. The Assignors hereby authorize and request the Commissioner of Patents and Trademarks to issue said Letters Patent stemming from the '277 Application to said Assignees.

The Assignors warrant to be the owner of the entire right, title and interest in said invention or improvements and to have the right to make this Assignment, and further warrant that there are no outstanding prior assignments, licenses, or other encumbrances on the interest herein assigned.

The Assignors hereby agree, upon the request and at the expense of said Assignees, their successors and assigns, to execute any and all continuation, continuation-in-part, divisional, extension, renewal, and substitute applications for

said invention or improvements, and any necessary oath, affidavit or declaration relating thereto, and any application for the reissue, reexamination or extension of any Letters Patent that may be granted upon said application, that said Assignees, their successors or assigns may deem necessary or expedient; and to cooperate to the best of the ability of the Assignors with said Assignees, their successors and assigns, in any proceedings or transactions involving such applications or patents, including the preparation and execution of preliminary statements, giving and producing evidence, and performing any and all other acts necessary to obtain said Letters Patent in the United States, and vest all rights therein hereby conveyed in the Assignees, their successors and assigns, whereby said Letters Patent will be held and enjoyed by the said Assignees, their successors and assigns, to the full end of the term for which said Letters Patent will be granted, as fully and entirely as the same would have been held and enjoyed by the Assignors if this Assignment had not been made.

By way of an Addendum to Patent Assignments, which was executed on May 19, 2010 and June 2, 2010, Ganymed Pharmaceuticals AG ("Ganymed") and Johannes Gutenberg-Universität Mainz ("Universität Mainz") have acknowledged that, as to the relationship between the Ganymed and Universität Mainz, the terms of this Assignment shall be subject to the terms of the Cooperation Treaties entered into between Universität Mainz and Ganymed dated June 28, 2005 and December 30, 2008, including, but not limited to, Articles 2.3.1 - 2.3.8 of the Treaty dated June 28, 2005 and Articles 2.3.1 - 2.3.9 of the Treaty dated December 30, 2008. In the event of any conflict or inconsistency between the terms of the Cooperation Treaties and the terms of this Assignment, the terms of the Cooperation Treaties shall supersede and govern.

This Assignment shall be binding upon and shall inure to the benefit of the Assignees and Assignors and their respective successors and assigns.

This Assignment may be executed in one or more counterparts, all of which shall be considered one and the same Assignment. The signatures from each counterpart may be combined with a copy of the Assignment to constitute the entire Assignment.

[SIGNATURE PAGES FOLLOW]

EXECUTED this 06 day of 11, 2012.



Ugur Sahin

WITNESSED by Ayhan Cavus Kati this 06 day of Nov, 2012.

EXECUTED this _____ day of _____, 2012.

Özlem Türeci

WITNESSED by _____ this _____ day of _____, 2012.

EXECUTED this _____ day of _____, 2012.

Michael Koslowski

WITNESSED by _____ this _____ day of _____, 2012.

EXECUTED this _____ day of _____, 2012.

Rita Mitnacht-Kraus

WITNESSED by _____ this _____ day of _____, 2012.

PATENT ASSIGNMENT

WHEREAS, we, Ugur Sahin, Özlem Türeci, Michael Koslowski, and Rita Mitnacht-Kraus (collectively the "the Assignors") have made new and useful inventions and improvements disclosed in a United States patent application entitled "MONOCLONAL ANTIBODIES FOR TREATMENT OF CANCER" and identified as Case No. 25923US01 in the offices of McANDREWS, HELD & MALLOY, LTD., filed on September 20, 2012, in the United States Patent and Trademark Office as Serial No. 13/636,277 (the "277 Application").

WHEREAS, Ganymed Pharmaceuticals AG, a German corporation having a place of business at Freiligrathstrasse 12, Mainz, Germany 55131, together with Johannes Gutenberg-Universität Mainz, having a place of business at Saarstrasse 21, Mainz, Germany 55122, (collectively "the Assignees") is desirous of acquiring the title, rights, benefits, and privileges hereinafter recited.

NOW, THEREFORE, in exchange for good and valuable consideration in hand paid the receipt, adequacy, and sufficiency of which are hereby acknowledged, the Assignors hereby assign to the Assignees, their successors and assigns, the entire right, title and interest in and to said application and the inventions and improvements disclosed therein, and in any and all other United States (provisional or non-provisional) applications based thereon or that claim priority thereto, including any continuation, continuation-in-part, divisional application that the Assignors may file, either solely or jointly with others, and in any and all Letters Patent of the United States that may be obtained on any of said applications, and in any reexamination, renewal, substitution, reissue or extension of such applications or patents, and every priority right that is or may be predicated upon or arise from said inventions, improvements, applications, and Letters Patent.

The Assignors hereby authorize the Assignees to file patent applications in any or all countries for any or all of said inventions and improvements in our name or in the names of the Assignees or otherwise as said Assignees may deem advisable, under the International Convention or otherwise. The Assignors further acknowledge the assignment of all domestic and foreign intellectual property rights to the Assignee(s) related to the '277 Application. The Assignors hereby authorize and request the Commissioner of Patents and Trademarks to issue said Letters Patent stemming from the '277 Application to said Assignees.

The Assignors warrant to be the owner of the entire right, title and interest in said invention or improvements and to have the right to make this Assignment, and further warrant that there are no outstanding prior assignments, licenses, or other encumbrances on the interest herein assigned.

The Assignors hereby agree, upon the request and at the expense of said Assignees, their successors and assigns, to execute any and all continuation, continuation-in-part, divisional, extension, renewal, and substitute applications for

said invention or improvements, and any necessary oath, affidavit or declaration relating thereto, and any application for the reissue, reexamination or extension of any Letters Patent that may be granted upon said application, that said Assignees, their successors or assigns may deem necessary or expedient; and to cooperate to the best of the ability of the Assignors with said Assignees, their successors and assigns, in any proceedings or transactions involving such applications or patents, including the preparation and execution of preliminary statements, giving and producing evidence, and performing any and all other acts necessary to obtain said Letters Patent in the United States, and vest all rights therein hereby conveyed in the Assignees, their successors and assigns, whereby said Letters Patent will be held and enjoyed by the said Assignees, their successors and assigns, to the full end of the term for which said Letters Patent will be granted, as fully and entirely as the same would have been held and enjoyed by the Assignors if this Assignment had not been made.

By way of an Addendum to Patent Assignments, which was executed on May 19, 2010 and June 2, 2010, Ganymed Pharmaceuticals AG ("Ganymed") and Johannes Gutenberg-Universität Mainz ("Universität Mainz") have acknowledged that, as to the relationship between the Ganymed and Universität Mainz, the terms of this Assignment shall be subject to the terms of the Cooperation Treaties entered into between Universität Mainz and Ganymed dated June 28, 2005 and December 30, 2008, including, but not limited to, Articles 2.3.1 - 2.3.8 of the Treaty dated June 28, 2005 and Articles 2.3.1 - 2.3.9 of the Treaty dated December 30, 2008. In the event of any conflict or inconsistency between the terms of the Cooperation Treaties and the terms of this Assignment, the terms of the Cooperation Treaties shall supersede and govern.

This Assignment shall be binding upon and shall inure to the benefit of the Assignees and Assignors and their respective successors and assigns.

This Assignment may be executed in one or more counterparts, all of which shall be considered one and the same Assignment. The signatures from each counterpart may be combined with a copy of the Assignment to constitute the entire Assignment.


[SIGNATURE PAGES FOLLOW]

EXECUTED this _____ day of _____, 2012.

Ugur Sahin

WITNESSED by _____ this _____ day of _____, 2012.

EXECUTED this 07 day of November, 2012.



Ozlem Tureci


WITNESSED by Aygun Cavas-Krali this 07 day of November, 2012.

EXECUTED this _____ day of _____, 2012.

Michael Koslowski

WITNESSED by _____ this _____ day of _____, 2012.

EXECUTED this 08 day of Nov., 2012.



Rita Mitnacht-Kraus

WITNESSED by Aygun Cavas-Krali this 08 day of Nov., 2012.

PATENT ASSIGNMENT

WHEREAS, we, Ugur Sahin, Özlem Türeci, Michael Koslowski, and Rita Mitnacht-Kraus (collectively the "the Assignors") have made new and useful inventions and improvements disclosed in a United States patent application entitled "MONOCLONAL ANTIBODIES FOR TREATMENT OF CANCER" and identified as Case No. 25923US01 in the offices of McANDREWS, HELD & MALLOY, LTD., filed on September 20, 2012, in the United States Patent and Trademark Office as Serial No. 13/636,277 (the "277 Application").

WHEREAS, Ganymed Pharmaceuticals AG, a German corporation having a place of business at Freiligrathstrasse 12, Mainz, Germany 55131, together with Johannes Gutenberg-Universität Mainz, having a place of business at Saarstrasse 21, Mainz, Germany 55122, (collectively "the Assignees") is desirous of acquiring the title, rights, benefits, and privileges hereinafter recited.

NOW, THEREFORE, in exchange for good and valuable consideration in hand paid the receipt, adequacy, and sufficiency of which are hereby acknowledged, the Assignors hereby assign to the Assignees, their successors and assigns, the entire right, title and interest in and to said application and the inventions and improvements disclosed therein, and in any and all other United States (provisional or non-provisional) applications based thereon or that claim priority thereto, including any continuation, continuation-in-part, divisional application that the Assignors may file, either solely or jointly with others, and in any and all Letters Patent of the United States that may be obtained on any of said applications, and in any reexamination, renewal, substitution, reissue or extension of such applications or patents, and every priority right that is or may be predicated upon or arise from said inventions, improvements, applications, and Letters Patent.

The Assignors hereby authorize the Assignees to file patent applications in any or all countries for any or all of said inventions and improvements in our name or in the names of the Assignees or otherwise as said Assignees may deem advisable, under the International Convention or otherwise. The Assignors further acknowledge the assignment of all domestic and foreign intellectual property rights to the Assignee(s) related to the '277 Application. The Assignors hereby authorize and request the Commissioner of Patents and Trademarks to issue said Letters Patent stemming from the '277 Application to said Assignees.

The Assignors warrant to be the owner of the entire right, title and interest in said invention or improvements and to have the right to make this Assignment, and further warrant that there are no outstanding prior assignments, licenses, or other encumbrances on the interest herein assigned.

The Assignors hereby agree, upon the request and at the expense of said Assignees, their successors and assigns, to execute any and all continuation, continuation-in-part, divisional, extension, renewal, and substitute applications for

said invention or improvements, and any necessary oath, affidavit or declaration relating thereto, and any application for the reissue, reexamination or extension of any Letters Patent that may be granted upon said application, that said Assignees, their successors or assigns may deem necessary or expedient; and to cooperate to the best of the ability of the Assignors with said Assignees, their successors and assigns, in any proceedings or transactions involving such applications or patents, including the preparation and execution of preliminary statements, giving and producing evidence, and performing any and all other acts necessary to obtain said Letters Patent in the United States, and vest all rights therein hereby conveyed in the Assignees, their successors and assigns, whereby said Letters Patent will be held and enjoyed by the said Assignees, their successors and assigns, to the full end of the term for which said Letters Patent will be granted, as fully and entirely as the same would have been held and enjoyed by the Assignors if this Assignment had not been made.

By way of an Addendum to Patent Assignments, which was executed on May 19, 2010 and June 2, 2010, Ganymed Pharmaceuticals AG ("Ganymed") and Johannes Gutenberg-Universität Mainz ("Universität Mainz") have acknowledged that, as to the relationship between the Ganymed and Universität Mainz, the terms of this Assignment shall be subject to the terms of the Cooperation Treaties entered into between Universität Mainz and Ganymed dated June 28, 2005 and December 30, 2008, including, but not limited to, Articles 2.3.1 - 2.3.8 of the Treaty dated June 28, 2005 and Articles 2.3.1 - 2.3.9 of the Treaty dated December 30, 2008. In the event of any conflict or inconsistency between the terms of the Cooperation Treaties and the terms of this Assignment, the terms of the Cooperation Treaties shall supersede and govern.

This Assignment shall be binding upon and shall inure to the benefit of the Assignees and Assignors and their respective successors and assigns.

This Assignment may be executed in one or more counterparts, all of which shall be considered one and the same Assignment. The signatures from each counterpart may be combined with a copy of the Assignment to constitute the entire Assignment.

[SIGNATURE PAGES FOLLOW]

EXECUTED this _____ day of _____, 2012.

Ugur Sahin


WITNESSED by _____ this _____ day of _____, 2012.

EXECUTED this _____ day of _____, 2012.


Özlem Türeci

WITNESSED by _____ this _____ day of _____, 2012.

EXECUTED this 23 day of Nov, 2012.



Michael Koslowski

WITNESSED by  this 23 day of Nov, 2012.

EXECUTED this _____ day of _____, 2012.

Rita Mitnacht-Kraus

WITNESSED by _____ this _____ day of _____, 2012.